India’s Glenmark Establishes Unit In Romania
This article was originally published in PharmAsia News
India's Glenmark Pharmaceuticals has established a new unit in Romania to produce specialty drugs. Glenmark sees a $50 million market in Romania within the next five years. Romania recently was admitted into the European Union and becomes the third European country to see a Glenmark unit established. (Click here for more
You may also be interested in...
MUMBAI - Indian drug maker Glenmark Pharmaceuticals will launch a division in Poland by acquiring seven generic pharmaceutical brands from Actavis, the Iceland-based generics major, and its Polish affiliate Biovena. The buy provides Glenmark an entry into the Polish market, estimated to be the largest in Central and East Europe
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.